290 related articles for article (PubMed ID: 22887791)
21. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients.
Trifilio S; Pennick G; Pi J; Zook J; Golf M; Kaniecki K; Singhal S; Williams S; Winter J; Tallman M; Gordon L; Frankfurt O; Evens A; Mehta J
Cancer; 2007 Apr; 109(8):1532-5. PubMed ID: 17351937
[TBL] [Abstract][Full Text] [Related]
22. Voriconazole therapy in children with cystic fibrosis.
Hilliard T; Edwards S; Buchdahl R; Francis J; Rosenthal M; Balfour-Lynn I; Bush A; Davies J
J Cyst Fibros; 2005 Dec; 4(4):215-20. PubMed ID: 16243008
[TBL] [Abstract][Full Text] [Related]
23. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
Sambatakou H; Dupont B; Lode H; Denning DW
Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
[TBL] [Abstract][Full Text] [Related]
24. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases.
Mouas H; Lutsar I; Dupont B; Fain O; Herbrecht R; Lescure FX; Lortholary O;
Clin Infect Dis; 2005 Apr; 40(8):1141-7. PubMed ID: 15791514
[TBL] [Abstract][Full Text] [Related]
25. [Usefulness of monitoring plasma voriconazole concentration in patients with chronic necrotizing pulmonary aspergillosis].
Hagiwara E; Shiihara J; Matsushima A; Enomoto T; Tagawa A; Sekine A; Tsuchiya N; Baba T; Shinohara T; Endo T; Sogo Y; Nishihira R; Komatsu S; Kato T; Ogura T; Takahashi H
Nihon Kokyuki Gakkai Zasshi; 2009 Feb; 47(2):93-7. PubMed ID: 19260530
[TBL] [Abstract][Full Text] [Related]
26. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.
Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS
Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
Denning DW; Ribaud P; Milpied N; Caillot D; Herbrecht R; Thiel E; Haas A; Ruhnke M; Lode H
Clin Infect Dis; 2002 Mar; 34(5):563-71. PubMed ID: 11807679
[TBL] [Abstract][Full Text] [Related]
28. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
Seyedmousavi S; Mouton JW; Verweij PE; Brüggemann RJ
Expert Rev Anti Infect Ther; 2013 Sep; 11(9):931-41. PubMed ID: 24053274
[TBL] [Abstract][Full Text] [Related]
30. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic drug monitoring of voriconazole in children.
Chen J; Chan C; Colantonio D; Seto W
Ther Drug Monit; 2012 Feb; 34(1):77-84. PubMed ID: 22210097
[TBL] [Abstract][Full Text] [Related]
32. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
Walsh TJ; Lutsar I; Driscoll T; Dupont B; Roden M; Ghahramani P; Hodges M; Groll AH; Perfect JR
Pediatr Infect Dis J; 2002 Mar; 21(3):240-8. PubMed ID: 12005089
[TBL] [Abstract][Full Text] [Related]
33. [Analysis of voriconazole serum concentrations and safety profile in pediatric oncology patients].
Silva F; Navea D; Saias C; Torres JP; Catalán P; Morales J
Rev Chilena Infectol; 2016 Apr; 33(2):127-34. PubMed ID: 27314989
[TBL] [Abstract][Full Text] [Related]
34. Determination of saliva trough levels for monitoring voriconazole therapy in immunocompromised children and adults.
Michael C; Bierbach U; Frenzel K; Lange T; Basara N; Niederwieser D; Mauz-Körholz C; Preiss R
Ther Drug Monit; 2010 Apr; 32(2):194-9. PubMed ID: 20216120
[TBL] [Abstract][Full Text] [Related]
35. Voriconazole-associated severe hyponatremia.
Kim KH; Lee S; Lee S; Yun NR; Kim NJ; Yu KS; Jang IJ; Park WB; Oh MD
Med Mycol; 2012 Jan; 50(1):103-5. PubMed ID: 21671829
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient.
Pea F; Baccarani U; Tavio M; Cojutti P; Adani GL; Londero A; Baraldo M; Franceschi L; Furlanut M; Viale P
Ann Pharmacother; 2008 Nov; 42(11):1711-6. PubMed ID: 18812562
[TBL] [Abstract][Full Text] [Related]
37. A retrospective analysis of the effect of patient-specific factors on voriconazole concentrations in oncology patients.
Lombardi LR; Miano TA; Davis JL; Morgan SC; Goldstein SC; Vardhanabhuti S; Mitra N; Vozniak JM
J Oncol Pharm Pract; 2012 Mar; 18(1):3-9. PubMed ID: 21350019
[TBL] [Abstract][Full Text] [Related]
38. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
Przepiorka D; Buadi FK; McClune B
Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
[TBL] [Abstract][Full Text] [Related]
39. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.
Siwek GT; Pfaller MA; Polgreen PM; Cobb S; Hoth P; Magalheas-Silverman M; Diekema DJ
Diagn Microbiol Infect Dis; 2006 Jul; 55(3):209-12. PubMed ID: 16626917
[TBL] [Abstract][Full Text] [Related]
40. Initial voriconazole trough blood levels and clinical outcomes of invasive aspergillosis in patients with hematologic malignancies.
Lee YJ; Lee SO; Choi SH; Kim YS; Woo JH; Chun S; Kim DY; Lee JH; Lee JH; Lee KH; Kim SH
Med Mycol; 2013 Apr; 51(3):324-30. PubMed ID: 22712456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
